Alkermes plc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALKS Nasdaq 2836 www.alkermes.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alkermes plc

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026 - Jun 17th, 2026 2:15 pm
ALKS' Sleep Disorder Drug Gets Orphan Drug Tags in the U.S. & Europe - Jun 16th, 2026 8:15 am
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe - Jun 15th, 2026 5:00 am
Rapport ‘fully prepared’ to launch seizure drug solo, CEO says - Jun 12th, 2026 3:31 am
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears - Jun 10th, 2026 12:08 pm
Should Alkermes’ Stronger Q1 2026 Results and Sleep-Medicine Advances Prompt Action From ALKS Investors? - Jun 7th, 2026 9:08 pm
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report? - Jun 5th, 2026 9:30 am
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue? - Jun 4th, 2026 9:30 am
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research - Jun 4th, 2026 5:00 am
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - Jun 3rd, 2026 2:05 pm
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting - May 26th, 2026 5:00 am
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences - May 21st, 2026 5:00 am
Alkermes' (NASDAQ:ALKS) Soft Earnings Are Actually Better Than They Appear - May 13th, 2026 12:35 pm
Sector Update: Healthcare Stocks Advance Late Afternoon - May 12th, 2026 1:58 pm
Sector Update: Healthcare Stocks Gain in Afternoon Trading - May 12th, 2026 11:54 am
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia - May 12th, 2026 5:00 am
Alkermes' Q1 Revenue Beat Highlights 'Underappreciated' Core Business, RBC Says - May 6th, 2026 10:37 am
Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises - May 6th, 2026 10:06 am
Alkermes plc Q1 2026 Earnings Call Summary - May 5th, 2026 2:46 pm
Alkermes (ALKS) Q1 2026 Earnings Transcript - May 5th, 2026 2:11 pm